1. MultiOmyxTM
Tumor Infiltrating
Lymphocyte Panel*
Comprehensive Immunophenotyping from a Single Slide
Immunotherapy is a promising new cancer treatment approach. In
order to develop effective precision immunotherapies, it is important
to identify immune checkpoint targets and the types and locations
of immune cells in the tumor microenvironment; e.g., B cells,
T cells, others.
The MultiOmyx Tumor Infiltrating Lymphocyte Panel provides the ideal
solution: Quantitative analytical results from every cell on your single
FFPE slide.
• Comprehensive immune profiling on a single FFPE slide
Tissue samples are precious. Unlike IHC assays which must
be performed on serial tissue sections, the MultiOmyx Tumor
Infiltrating Lymphocyte Panel evaluates 12 key markers on a
single slide.
• Unambiguous individual cell phenotyping
The MultiOmyx Tumor Infiltrating Lymphocyte Panel definitively
differentiates cell phenotypes and characterizes immune activation
and suppression in relation to tumor and stromal regions.
• Advanced bio-image informatics
Analysis algorithms provide quantitative expression,
co-expression, and co-localization of markers.
• Rigorous quality management system
The MultiOmyx Tumor Infiltrating Lymphocyte Panel is offered by
Clarient a NeoGenomics Company, which is CAP accredited
and CLIA certified. Quality management overseen by dedicated
pathologist and Medical Director.
12 cancer immune markers on a single
FFPE slide. Provides quantitative
analytical results from every cell.
Figure courtesy of Dr. Luster, Cancer Immunol Res; 2(12); 1125-31.
2014 AACR
CD3 T cell
CD4 TH (helper)
CD8 TC (cytotoxic)
CD20 B cell
CD68 Macrophage
CD56 NK cell
CD45RO Memory T cell
PD-L1 PD1 Ligand
PD1 Inhibit T cell activation
CTLA-4 Inhibit T cell activation
FOXP3 Treg
pan-CK Epithelial Cell
MultiOmyx
Comprehensive immune profiling
Evaluate 12 key markers on a single slide. Immune markers shown:
CD4 (green), CD8 (red), PD-L1 (magenta), CD68 (cyan), pan-CK (yellow).
IF Color Blends
Unambiguous individual cell phenotyping
Differentiates cell phenotypes and characterizes immune activation and
suppression in relation to tumor and stromal regions.
Classification Color Blends

2. Customer will receive a report summarizing cell counts, percentage, and density for the sample
For additional information and ordering, please contact Rafael Casiano at rafael.casiano@neogenomics.com,
813-330-7555.
In addition, a data package will accompany the report including:
• Cell count data in common spreadsheet format → Tab-delimited text files
• Registered, normalized AF removed IF images → One per marker per ROI
• Image QC mask images → One per marker per ROI
• Positive-cell masks → One per marker per ROI
• Pre-specified color blends → One per marker per ROI consisting of IF stain (red), cell positive call (green), nuclear mask (blue)
• Concatenated multiple sample data
12701 Commonwealth Dr., Suite 9
Fort Myers, FL 33913
neogenomics.com | clarient.com
© 2016 NeoGenomics Laboratories, Inc.
© 2016 Clarient Diagnostic Services, Inc.
All rights reserved.
MultiOmyx is a registered trademark of NeoGenomics Laboratories, Inc.,
which holds a license from GE Healthcare BioSciences Corp.
All other trademarks are the property of their respective owners.
Rev. 032916
Expression Phenotype
Epithelial / Tumor
Cell Count = 20,501
Non-Epithelial / Stromal
Cell Count = 117,040
Total
Cell Count = 137,541
Count % Density Count % Density Count %
CD3+ T 10,235 50 2,047 58,580 50 11,716 68,815 50
CD4+ CD4+ 8,247 40 1,649 25,335 22 5,067 33,582 24
CD8+ CD8+ 2,019 10 404 33,125 28 6,625 35,144 26
Remaining 9 single
biomarkers
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
CD3+CD4+ T helper 8,014 39 1,603 23,033 20 4,607 31,047 23
CD3+CD4+FOXP3+ T regulatory 4,176 20 835 3,055 3 611 7,231 5
CD3+CD4+FOXP3+
PD-L1+
Immuno-suppression,
T regulatory
15 0 3 32 0 6 47 0
CD3+CD4+CD45RO+ Memory T helper 2,294 11 459 17,438 15 3,488 19,732 14
CD3+CD4+PD1+ Anergic T helper 35 0 7 68 0 14 103 0
CD3+CD4+CTLA-4+
Downregulate activated
T helper
2,597 13 519 23 0 5 2,620 2
CD3+CD8+ T cytotoxic 1,989 10 398 32,985 28 6,597 34,974 25
CD3+CD8+CD45RO+ Memory T cytotoxic 1,674 8 335 28,556 24 5,711 30,230 22
CD3+CD8+PD1+ Anergic T cytotoxic 744 4 149 2,232 2 446 2,976 2
CD3+CD8+CTLA-4+
Downregulate activated
T cytotoxic
1,116 5 223 837 1 167 1,953 1
CD3-CD68+ Macrophage 2,166 11 433 27,116 23 5,423 29,282 21
CD3-CD68+PD-L1+
Immuno-suppression,
macrophage
1,463 7 293 6,689 6 1,338 8,152 6
CD3-CD20+ B 233 1 47 5,482 5 1,096 5,715 4
CD3-CD20+PD-L1+ Immuno-suppression, B 52 0 10 63 0 13 115 0
CD3-CD56+ Natural killer 113 1 23 6,271 5 1,254 6,384 5
CD3-CD8+CD56+ Natural killer T 50 0 10 731 1 146 781 1
Pan-CK+PD-L1+
Immuno-suppression,
tumor
15,476 75 3,095 15 0 3 15,491 11
•
•
•
* For research use only — Validation pending